The assessment of the beta-blocking activity of urapidil: A new method

M. J. Jamieson; S. H.D. Jackson; S. S. Patel; A. M.M. Shepherd; H. Galbraith; W. Stewart; P. H. Flanagan

doi:10.1007/BF00606651

The assessment of the beta-blocking activity of urapidil: A new method

M. J. Jamieson, S. H.D. Jackson, S. S. Patel, A. M.M. Shepherd, H. Galbraith, W. Stewart, P. H. Flanagan

Medicine

Research output: Contribution to journal › Article

7 Scopus citations

Abstract

Urapidil is an antihypertensive vasodilator agent whose pharmacological action in man has not yet been fully defined. We have assessed the beta blocking activity of urapidil 15 mg and 30 mg i.v. in a single blind study of 10 healthy male volunteers. Urapidil at plasma concentrations in the same range as those shown to have antihypertensive affect did not significantly attenuate the chronotropic effect of isoproterenol. Propranolol 5 mg iv, the positive control, significantly shifted the isoproterenol dose-response curve to the right. We describe a new method of analyzing incomplete dose response curves whereby a linear terminal segment can be reproducibly defined.

Original language	English (US)
Pages (from-to)	149-154
Number of pages	6
Journal	European Journal of Clinical Pharmacology
Volume	31
Issue number	2
DOIs	https://doi.org/10.1007/BF00606651
State	Published - Mar 1 1986

Fingerprint

Keywords

urapidil
volunteers isoproterenol dose response analysis

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Cite this

Jamieson, M. J., Jackson, S. H. D., Patel, S. S., Shepherd, A. M. M., Galbraith, H., Stewart, W., & Flanagan, P. H. (1986). The assessment of the beta-blocking activity of urapidil: A new method. European Journal of Clinical Pharmacology, 31(2), 149-154. https://doi.org/10.1007/BF00606651

@article{e52cd0e6c221402499050869fff35a67,

title = "The assessment of the beta-blocking activity of urapidil: A new method",

abstract = "Urapidil is an antihypertensive vasodilator agent whose pharmacological action in man has not yet been fully defined. We have assessed the beta blocking activity of urapidil 15 mg and 30 mg i.v. in a single blind study of 10 healthy male volunteers. Urapidil at plasma concentrations in the same range as those shown to have antihypertensive affect did not significantly attenuate the chronotropic effect of isoproterenol. Propranolol 5 mg iv, the positive control, significantly shifted the isoproterenol dose-response curve to the right. We describe a new method of analyzing incomplete dose response curves whereby a linear terminal segment can be reproducibly defined.",

keywords = "urapidil, volunteers isoproterenol dose response analysis",

author = "Jamieson, {M. J.} and Jackson, {S. H.D.} and Patel, {S. S.} and Shepherd, {A. M.M.} and H. Galbraith and W. Stewart and Flanagan, {P. H.}",

year = "1986",

month = mar

day = "1",

doi = "10.1007/BF00606651",

language = "English (US)",

volume = "31",

pages = "149--154",

journal = "European Journal of Clinical Pharmacology",

issn = "0031-6970",

publisher = "Springer Verlag",

number = "2",

}

TY - JOUR

T1 - The assessment of the beta-blocking activity of urapidil

T2 - A new method

AU - Jamieson, M. J.

AU - Jackson, S. H.D.

AU - Patel, S. S.

AU - Shepherd, A. M.M.

AU - Galbraith, H.

AU - Stewart, W.

AU - Flanagan, P. H.

PY - 1986/3/1

Y1 - 1986/3/1

N2 - Urapidil is an antihypertensive vasodilator agent whose pharmacological action in man has not yet been fully defined. We have assessed the beta blocking activity of urapidil 15 mg and 30 mg i.v. in a single blind study of 10 healthy male volunteers. Urapidil at plasma concentrations in the same range as those shown to have antihypertensive affect did not significantly attenuate the chronotropic effect of isoproterenol. Propranolol 5 mg iv, the positive control, significantly shifted the isoproterenol dose-response curve to the right. We describe a new method of analyzing incomplete dose response curves whereby a linear terminal segment can be reproducibly defined.

AB - Urapidil is an antihypertensive vasodilator agent whose pharmacological action in man has not yet been fully defined. We have assessed the beta blocking activity of urapidil 15 mg and 30 mg i.v. in a single blind study of 10 healthy male volunteers. Urapidil at plasma concentrations in the same range as those shown to have antihypertensive affect did not significantly attenuate the chronotropic effect of isoproterenol. Propranolol 5 mg iv, the positive control, significantly shifted the isoproterenol dose-response curve to the right. We describe a new method of analyzing incomplete dose response curves whereby a linear terminal segment can be reproducibly defined.

KW - urapidil

KW - volunteers isoproterenol dose response analysis

UR - http://www.scopus.com/inward/record.url?scp=0022895239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022895239&partnerID=8YFLogxK

U2 - 10.1007/BF00606651

DO - 10.1007/BF00606651

M3 - Article

C2 - 2879734

AN - SCOPUS:0022895239

VL - 31

SP - 149

EP - 154

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 2

ER -

Access to Document

10.1007/BF00606651